Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as potent fibroblast growth factor receptor inhibitors
Open Access
- 9 June 2021
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 11 (34), 20651-20661
- https://doi.org/10.1039/d1ra02660g
Abstract
Abnormal activation of FGFR signaling pathway plays an essential role in various types of tumors. Therefore, targeting FGFRs represents an attractive strategy for cancer therapy. Herein, we report a series of 1H-pyrrolo[2,3-b]pyridine derivatives with potent activities against FGFR1, 2, and 3. Among them, compound 4h exhibited potent FGFR inhibitory activity (FGFR1–4 IC50 values of 7, 9, 25 and 712 nM, respectively). In vitro, 4h inhibited breast cancer 4T1 cell proliferation and induced its apoptosis. In addition, 4h also significantly inhibited the migration and invasion of 4T1 cells. Furthermore, 4h with low molecular weight would be an appealing lead compound which was beneficial to the subsequent optimization. In general, this research has been developing a class of 1H-pyrrolo[2,3-b]pyridine derivatives targeting FGFR with development prospects.Funding Information
- West China Hospital, Sichuan University (2018HXBH009)
- Fundamental Research Funds for the Central Universities (2020SCU12020)
This publication has 28 references indexed in Scilit:
- FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic InterventionInternational Journal of Molecular Sciences, 2020
- Recent advance in the development of novel, selective and potent FGFR inhibitorsEuropean Journal of Medicinal Chemistry, 2019
- Future applications of FGF/FGFR inhibitors in cancerExpert Review of Anticancer Therapy, 2018
- Design, synthesis and biological evaluation of a series of novel 2-benzamide-4-(6-oxy-N-methyl-1-naphthamide)-pyridine derivatives as potent fibroblast growth factor receptor (FGFR) inhibitorsEuropean Journal of Medicinal Chemistry, 2018
- Protein Tyrosine Phosphatase Receptor Type G (PTPRG) Controls Fibroblast Growth Factor Receptor (FGFR) 1 Activity and Influences Sensitivity to FGFR Kinase InhibitorsMolecular & Cellular Proteomics, 2018
- FGFR a promising druggable target in cancer: Molecular biology and new drugsCritical Reviews in Oncology/Hematology, 2017
- Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationOncotarget, 2016
- Discovery of 3-(5′-Substituted)-Benzimidazole-5-(1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis, and Biological EvaluationJournal of Medicinal Chemistry, 2016
- Blocking the FGF/FGFR system as a two-compartment antiangiogenic/antitumor approach in cancer therapyPharmacological Research, 2016
- FGF Receptors: Cancer Biology and TherapeuticsMedicinal Research Reviews, 2013